Related Experiment Video
Updated: Aug 16, 2026

Transport Properties of Ibuprofen Encapsulated in Cyclodextrin Nanosponge Hydrogels: A Proton HR-MAS NMR Spectroscopy Study
Published on: August 15, 2016
Inclusion complexation of lorazepam with different cyclodextrins suitable for parenteral use
Chantal Holvoet1, Yvan Vander Heyden, Jacqueline Plaizier-Vercammen
1Department of Pharmaceutical Technology and Physical Pharmacy, Vrije Universiteit Brussel-VUB, Brussels, Belgium.
Abstract:
The development of a parenteral lorazepam formulation, using cyclodextrins (CDs) as inclusion complexation agents, was investigated. CDs suitable for parenteral injection, i.e., hydroxypropyl-beta-cyclodextrin (HP-beta-CD), hydroxypropyl-gamma-cyclodextrin (HP-gamma-CD), sulfobutylether-7-beta-cyclodextrin (SBE-7-beta-CD), and maltosyl-beta-cyclodextrin (malt-beta-CD) were studied for the possibility to increase the solubility of lorazepam. Lorazepam interacted with all tested CD derivatives and 1:1 complexes are formed. HP-beta-CD exerts the highest solubility improvement, reaching about 6 mg/ml lorazepam in 30% (w/v) CD solution. When using SBE-7-beta-CD or malt-beta-CD only half of that concentration can be dissolved. HP-gamma-CD interacts much less with lorazepam. Parenteral solutions with 4 mg/ml in 30% (w/v) HP-beta-CD solution, with 2 mg/ml in 30% (w/v) SBE-7-beta-CD, and with 2 mg/ml lorazepam in 15% (w/v) HP-beta-CD, were prepared. Sterile filtration of the formulation needs to be applied because of massive degradation of lorazepam during autoclaving. No precipitation is observed after dilution of the different formulations with (physiological) water or with 5% dextrose in water, which proves their suitability for administration with perfusions. The stability of the preparations was investigated in aqueous medium. During the first month, in all solutions more than 90% of lorazepam remained; after 3 months, less than 60% of lorazepam remained in the solutions with 15% (w/v) HP-beta-CD and around 65-70% in the solutions with 30% (w/v) of CDs. Because of this short stability time, the preparations need to be lyophilized.
Related Concept Videos
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Oral Drug Delivery Systems: Continuous-Release Systems
Bioavailability Enhancement: Drug Permeability Enhancement
Modified-Release Drug Delivery Systems: Rate-Programmed II
Factors Influencing Drug Absorption: Pharmaceutical Parameters
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

